Zim Laboratories Limited — Important, 03-06-2025: General Updates

ZIM Laboratories has announced a board meeting to review the financial results for the quarter and half-year. FY25 operating income rose 7.4% YoY to ₹1,719 Cr, driven by 39% growth in Innovative Products (NIP + OTF), which now make up 36% of revenues. Exports advanced 17.9% to ₹1,343 Cr, expanding the company’s international footprint. EBITDA margin held at 23.2%, with PAT at ₹140 Cr, supported by cost efficiencies despite higher finance costs from CapEx. Strong R&D (7.7% of income) fuels complex generics and Thinoral® platform growth. Strategic partnerships and capacity upgrades support long-term expansion amid geopolitical and regulatory challenges.